Anti-interleukin-6 receptor antibody inhibits the progression in human colon carcinoma cells

European Journal of Clinical Investigation

Volumn 41, Issue 3, 2011, Pages 277-284

  Hsu, Chih Ping ^a   Chen, Yung Liang ^a   Huang, Chiu Chen ^b   Chou, Chih Chung ^a   Liu, Chia Ling ^a   Hung, Chih Hung ^a   Kao, Ting Yu ^a   Chung, Yuan Chiang ^c,d  

^a YUANPEI UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c TAO YUAN GENERAL HOSPITAL   (Taiwan)

^d Hsin Chu General Hospital   (Taiwan)

Author keywords

Clonogenic growth; Colorectal carcinoma; Interleukin 6; Invasiveness

Indexed keywords

ANTINEOPLASTIC AGENT; GELATINASE A; GELATINASE B; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 6 RECEPTOR ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CLONOGENESIS; COLORECTAL CARCINOMA; DRUG MECHANISM; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANALYSIS OF VARIANCE; CARCINOMA; CELL PROLIFERATION; COLONIC NEOPLASMS; DISEASE PROGRESSION; HUMANS; INTERLEUKIN-6; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTORS, INTERLEUKIN-6; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 79551663713     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02405.x     Document Type: Article

References (40)

1. Ishihara K, Hirano T. Interleukin-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 2002;13:357-68.
2. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 2004;94:1543-53.
3. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rational and clinical evidence. Clin Cancer Res 2003;9:4653-65.
4. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 2006;80:227-36.
5. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the JAK/STAT pathway. Cell 2002;109:S121-31.
6. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin-6 type cytokine signaling and its regulation. Biochem J 2003;374:1-20.
7. Fukuta R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor-1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinass signaling in colon cancer cells. J Biol Chem 2002;277:38205-11.
8. Su JL, Lai KP, Chen CA, Yang CY, Chen PS, Chang CC et al. A Novel peptide specifically binding to interleukin-6 receptor (gp 80) inhibits angiogenesis and tumor growth. Cancer Res 2005;65:4827-35.
9. Dankbar B, Padró T, Leo R, Feldmann B, Kropff M, Mesters RM et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000;95:2630-6.
10. Grant SL, Hammacher A, Douglas AM, Goss GA, Mansfield RK, Heath JK et al. An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells. Oncogene 2002;21:460-74.
11. Wang J, Asensio VC, Campbell IL. Cytokines and chemokines as mediators of protection and injury in the central nervous system assessed in transgenic mice. Curr Top Microbiol Immunol 2002;265:23-48.
12. Huang SP, Wu MS, Shun CT, Wang HP, Lin MT, Kuo ML et al. Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. J Biomed Sci 2004;11:517-27.
13. Burger RA, Grosen EA, Ioli GR, Van Eden ME, Park M, Berman ML et al. Spontaneous release of interleukin-6 by primary culture of lymphoid and tumor cell populations purified from human ovarian carcinoma. J Interferon Cytokine Res 1995;15:255-60.
14. Wu CW, Wang SR, Chao MF, Wu TC, Lui WY, P'eng FK et al. Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol 1996;91:1417-22.
15. Kiintongkaew S, Amornphimoltham P, Tapong B. Tumor-stoma interactions influence cytokine expression and matrix metalloproteinase activities in paired primary and metastatic head and neck cancer. Cell Biol Int 2009;33:165-73.
16. Rabinovich A, Medina L, Piura B, Segal S, Huleihel M. Recitation of ovariam carcinoma SKOV-3 cell proliferation and secretion of MMPs by antocrine IL-6. Anticancer Res 2007;27:267-72.
17. Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 2003;103:642-6.
18. Chung YC, Chang YF. Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 2003;83:222-6.
19. Riedel F, Zaiss I, Herzog D. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma. Anticancer Res 2005;25:2761-5.
20. George DJ, Halabi S, Shepard TF, Sanford B, Vogelzang NJ, Small EJ et al. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostatic cancer: results from cancer and leukemic group B 9480. Clin Cancer Res 2005;11:1815-20.
21. Kinoshita T, Ito H, Miki C. Serum interleukin-6 level reflects the tumor proliferate activity in patients with colorectal carcinoma. Cancer 1999;85:2526-31.
22. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myeloma. Nature 1988;332:83-5.
23. Oka M, Iizuka N, Yamamoto K, Gondo T, Abe T, Hazama S et al. The influence of interleukin-6 on the growth of human esophageal cancer cell lines. J Interferon Cytokine Res 1996;16:1001-6.
24. Knupfer H, Preiss R. Serum interleukin-6 levels in colorectal cancer patients a summary of published results. Int J Colorectal Dis 2010;25:135-40.
25. Hsu CP, Chung YC. Influence of interleukin-6 on the invasiveness of human colorectal carcinoma. Anticancer Res 2006;26:4607-14.
26. Chung YC, Chaen YL, Hsu CP. Clinical significance of tissue expression of interleukin-6 in colorectal carcinoma. Anticancer Res 2006;26:3905-11.
27. Chung YC, Lin CC, Chou CC, Hsu CP. The effect of Longan seed polyphenols on colorectal carcinoma cells. Eur J Clin Invest 2010;40:713-21.
28. Cos S, Fernández R, Güézmes A, Sánchez-Barceló EJ. Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res 1998;58:4383-90.
29. Schneider MR, Hoeflich A, Fischer JR, Wolf E, Sordat B, Lahm H. Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Lett 2000;151:31-8.
30. Podolsky DK. Inflammatory bowel disease. N Eng J Med 2002;347:417-29.
31. Atreya R, Neurath MF. Signal molecules: the pathogenic role of the IL-6/STAT-3 trans signaling pathway in intestinal inflammation and in colonic cancer. Curr Drug Targets 2008;9:369-74.
32. Fantini MC, Pallone F. Cytokines from gut inflammation to colorectal carcinoma. Carr Drug Targets 2008;9:375-80.
33. Wang LH. Molecular signaling regulating anchorage-independent growth of cancer cells. Mt Sinai J Med 2004;71:361-7.
34. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 2003;17:1263-93.
35. Edinger AL. Growth factors regulate cell survival by controlling nutrient transporter expression. Biochem Soc Trans 2005;33:225-7.
36. Fields AP, Frederick LA, Regala RP. Targeting the oncogenic protein kinase Ciota signalling pathway for the treatment of cancer. Biochem Soc Trans 2007;35:996-1000.
37. Grimberg A. Mechanisms by which IGF-I may promote cancer. Cancer Biol Ther 2003;2:630-5.
38. Khaleghpour K, Li Y, Banville D, Yu Z, Shen SH. Involvement of PI3-kinase signaling pathway in progression of colon adenocarcinoma. Carcinogenesis 2004;25:241-8.
39. Lin Q, Lai R, Chirieac LR, Li C, Thomazy VA, Grammatikakis I et al. Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol 2005;167:969-80.
40. Chen Y, Pawlikowska L, Yao JS. Interleukin-6 involvement in brain anteriovenous malformation. Ann Neurol 2006;59:72-80.